-
Clinical essentials: classification, diagnosis and treatment of familial hereditary prostate cancer
Time of Update: 2022-04-29
Opinions of the Risk Assessment and Genetic Testing Expert Group: It is recommended that the genetically high-risk population of prostate cancer who meets any of the following conditions consider germline mutation testing of DNA damage repair genes, including BRCA2, BRCA1, ATM, PALB2, CHEK2, MLH1, MSH2, MSH6, PMS2, etc.
-
FDA Approves Novartis Targeted Radioligand Therapy Today for Express Treatment of Prostate Cancer
Time of Update: 2022-04-29
S. FDA has approved the company’s targeted radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan, formerly known as 177Lu-PSMA-617) for the treatment of Prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) patients .
Retrieved March 23, 2022, from https:// release/2022/03/23/2408996/0/en/Novartis-PluvictoTM-approved-by-FDA-as-first-targeted-radioligand-therapy-for-treatment-of-progressive-PSMA-positive-metastatic-castration- resistant-prostate-cancer.
-
High-Risk Localized Prostate Cancer: Surgery vs. Radiation
Time of Update: 2022-04-29
Patients with high-risk but limited-scope prostate cancer often have a choice between surgery and radiation therapy, but randomized trials comparing outcomes in this patient population are lacking .
-
2021 Fifth Edition Update Highlights of the NCCN Bladder Cancer Guidelines
Time of Update: 2022-04-29
◆Adjuvant nivolumab Consider use in ypT2-ypT4a or ypN+ patients who have received prior neoadjuvant chemotherapy Consider adjuvant RT with nivolumab in T3-T4, node-positive, or border-positive patients (category 2B recommendation) Footnote added: Best suited for patients who value delayed chance of recurrence and consider the risk of adverse effects to be acceptable, and accept complete disease remission The chances of patients not improving .
-
EAU Guidelines for the Diagnosis and Treatment of Lower Urinary Tract Symptoms in Non-Neurogenic Women (Part 2)
Time of Update: 2022-04-29
Women with urethral strictures leading to BOO urethrotomy and postoperative urethral dilatation are given, but should be informed of the limited long-term improvement of symptoms and the risk of postoperative urinary incontinence (UI) with this therapy (strength of recommendation: weak) .
-
Carry out ketone reduction to the end - standardized management of testosterone in prostate cancer
Time of Update: 2022-04-29
Establish a scientific testosterone management model to further improve the overall survival of prostate cancer patients in China 1 .
Urology Branch of Chinese Medical Association, China Prostate Cancer Alliance.
-
VESPER study: dd-MVAC neoadjuvant chemotherapy significantly improves 3-year PFS in non-metastatic muscle-invasive bladder cancer
Time of Update: 2022-04-29
The results showed that HR of the treatment groups differed significantly by chemotherapy regimen, suggesting that adjuvant chemotherapy and NAC should not be used in combination (Table 2) .
-
Patients with urolithiasis: Empirical or selective prophylactic drug therapy reduces the incidence of stone-related events?
Time of Update: 2022-04-28
Table 2 HR multivariate analysis of stone-related time in patients who received and did not receive a 24-hour urine test before PPT Figure 2 shows the predicted probability of stone-related events within 2 years of follow-up in patients with recurrent USD .
-
Bladder cancer bladder preservation treatment points list
Time of Update: 2022-04-28
For high-risk NMIBC, after transurethral resection of bladder tumor (TURBT) combined with Bacillus Calmette-Guérin (BCG) intravesical instillation, RC is also recommended if BCG treatment fails .
-
High incidence of nocturnal polyuria in women with overactive bladder
Time of Update: 2022-04-28
The results of the ROC analysis revealed that more than 5 episodes of nocturia in the 3-day voiding diary were the cut-off values for predicting nocturnal polyuria (sensitivity=85%, specificity=61%, area=0.
-
Darotamide combined with ADT improves survival in patients with hormone-sensitive metastatic prostate cancer
Time of Update: 2022-04-28
ADT Intensification in Hormone-Sensitive Metastatic Prostate Cancer: A Review of Evolving Treatment Options by Robert Dreicer, MD, MS , MACP, FASCO Addition of dalotamide to androgen deprivation therapy combined with docetaxel improves survival .
-
Single-incision surgery for female stress urinary incontinence, supported by high-quality evidence Juran Review
Time of Update: 2022-04-27
These results suggest that Adjust and Altis (the two main slings included in this study) single-incision sling midurethral suspension is non-inferior to standard retropubic and transobturator midurethral suspensions in terms of subjective success rates at 15-month follow-up.
-
ACS Nano Harbin Medical University Xu Wanhai/Wang Hao/Wang Lu and others developed a new type of hydrogel that can achieve reversible "ligation" for men
Time of Update: 2022-04-27
On March 30, 2022, Xu Wanhai, Wang Hao, Wang Lu and Qiao Zengying of the National Center for Nanoscience and Technology of Harbin Medical University published a joint communication online at ACS Nano (IF=16) entitled "An Ultrasound-Induced Self-Clearance Hydrogel for Male Reversible" Contraception” research paper in which ultrasound (US)-induced self-clearing hydrogels monitored in real time were used for in situ injection into the vas deferens, enabling effective contraception and non-invasive recanalization when needed .
-
This article summarizes the technical points of flexible ureteroscopic lithotripsy
Time of Update: 2022-04-27
Preoperative stents 71% of experts recommend rigid ureteroscopy to assess and/or dilate the ureter before insertion of the ureteral access sheath, but there is a risk of ureteral injury and decompression bleeding .
-
【ASCO GU 2022】Olapari prostate cancer has another success, benefiting the entire first-line population of mCRPC
Time of Update: 2022-03-09
The main results of the study were presented at the 2019 ESMO meeting: In patients with mCRPC who have progressed on novel endocrine therapy and carry BRCA1/2 or ATM mutations, Ola compared with new endocrine therapy drugs such as enzalutamide or abiraterone.
-
Molecular Cancer Xuzhou Medical University multi-unit cooperation, Han Conghui/Chen Zhesheng discovered the potential molecular mechanism of cisplatin resistance in bladder urothelial carcinoma
Time of Update: 2022-03-09
iNature The overall response to cisplatin-based chemotherapy in bladder urothelial carcinoma (BUC) remains unsatisfactory due to complex pathological subtypes, genomic differences, and drug resistance .
In conclusion, this study demonstrates that HNRNPU expression is associated with cisplatin sensitivity in bladder urothelial carcinoma cells .
-
Express complete remission rate of 83%, positive early clinical results of non-viral gene therapy for bladder cancer
Time of Update: 2022-03-09
▎WuXi AppTec content team editor enGene announced today that EG-70, an innovative non-viral gene therapy for local administration in mucosal tissue based on its proprietary technology platform, is used in the treatment of high-grade non-muscle infiltrates unresponsive to Bacille Calmette-Guerin (BCG) Positive results from a phase 1/2 clinical trial in patients with meningococcal bladder cancer (NMIBC) .
-
Insights Frontier 40% of men with lower urinary tract symptoms can avoid unnecessary prostate cancer tests
Time of Update: 2022-03-09
Table 2 After the onset of symptoms, the incidence of prostate cancer in each GRS group within 2 years The combined risk model of GRS + age was more predictive Figure 3), significantly better than the two individual covariates, GRS AUC of 0.
-
Article Summary: Symptoms, Diagnosis, and Treatment of undescended testes
Time of Update: 2022-03-09
Treating undescended testes in infancy is likely to reduce the risk of future complications, such as infertility and testicular cancer .
The undescended testicles, which are located in the abdomen, have a greater risk of developing testicular cancer than the groin .
-
Specialized in protecting the bladder: precise radiofrequency resection of bladder tumors and techniques
Time of Update: 2022-03-09
Research and development of plasma needle ring electrodes and bladder tumor removal baskets to provide a total solution for transurethral resection of bladder tumors; 4.
Creation of super transurethral resection of bladder tumor (STURBT), and report at the AUA annual meeting; 7.
